Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Equillium Inc (EQ)

Equillium Inc (EQ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19

Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.

REGN : 503.66 (-0.29%)
LLY : 143.81 (-0.93%)
EQ : 4.91 (-2.58%)
VIR : 31.66 (+2.26%)
Equillium Provides Itolizumab COVID-19 Program Update

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that due to the rapidly evolving COVID-19...

EQ : 4.91 (-2.58%)
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter...

EQ : 4.91 (-2.58%)
Equillium to Present at Investor Conferences in November 2020

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium's chief executive...

EQ : 4.91 (-2.58%)
Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

Studies further validate ongoing clinical development of itolizumab for the treatment of systemic lupus erythematosus and lupus nephritis

EQ : 4.91 (-2.58%)
Is Equillium (EQ) Stock Outpacing Its Medical Peers This Year?

Is (EQ) Outperforming Other Medical Stocks This Year?

EQ : 4.91 (-2.58%)
Stocks in play: EQ Inc.

Published an updated Research Report after EQ Works released its second quarter of 2020 financial statements. ...

EQ : 4.91 (-2.58%)
EQ Works Reports Data Revenue Continues to Grow Despite Slower COVID-19 Quarter

eResearch Corp. (www.eresearch.com) published an updated Research Report after EQ Works (TSXV: EQ ...

RAMP : 60.60 (+3.29%)
TTD : 886.90 (+2.30%)
CYPXF : 1.0300 (unch)
EQ : 4.91 (-2.58%)
Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that data supporting the CD6-ALCAM pathway...

EQ : 4.91 (-2.58%)
Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients

Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020

EQ : 4.91 (-2.58%)
Equillium to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today...

EQ : 4.91 (-2.58%)
Equillium Announces Closing of Public Offering of Common Stock

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced...

EQ : 4.91 (-2.58%)
Equillium Announces Pricing of Public Offering of Common Stock

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the pricing of an underwritten public offering...

EQ : 4.91 (-2.58%)
Equillium Announces Proposed Public Offering of Common Stock

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it intends to offer and sell shares...

EQ : 4.91 (-2.58%)
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the second quarter...

EQ : 4.91 (-2.58%)
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

The Virtual Summer Summit will take place on June 9-12, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below...

ACCO : 8.13 (+1.75%)
ALIM : 4.68 (+2.18%)
ANVS : 5.36 (-0.74%)
AQB : 5.94 (+4.39%)
ARTL : 0.6489 (-1.68%)
AVLNF : 0.0900 (-6.83%)
BLCM : 3.05 (-0.65%)
NDRA : 0.8360 (-3.91%)
EFOI : 4.89 (+1.03%)
EQ : 4.91 (-2.58%)
EXROF : 3.0900 (-6.08%)
HL : 5.06 (-3.07%)
HSII : 26.93 (+0.11%)
HSDT : 0.4179 (-0.50%)
HGBL : 1.7773 (+1.56%)
IPWR : 8.00 (-0.99%)
LINC : 6.26 (+2.29%)
MBII : 1.1700 (+0.86%)
MLSS : 1.8600 (+3.91%)
MYSZ : 1.2900 (+1.57%)
NBEV : 3.30 (-0.30%)
ONCS : 5.55 (-2.63%)
OGEN : 0.4876 (-0.49%)
SFE : 6.36 (-1.70%)
SLS : 3.61 (-0.82%)
PIXY : 2.29 (-2.55%)
SGLB : 2.75 (+1.10%)
SOTK : 4.0500 (unch)
TNXP : 0.6170 (-2.06%)
TGA : 0.5129 (+0.57%)
URG : 0.5400 (+2.37%)
Equillium to Present at Jefferies Virtual Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today...

EQ : 4.91 (-2.58%)
Equillium Reports First Quarter 2020 Financial Results

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 4.91 (-2.58%)
Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today...

EQ : 4.91 (-2.58%)
Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced...

LPBC : 6.9500 (+0.72%)
EQ : 4.91 (-2.58%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar